Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Buying Outside the Pharmacy: 45% of Peptide Users Who Source From Social Media Have Visited the ER

      Logo

      News provided by

      Sunlight

      May 21, 2026, 14:35 ET

      Share this article

      Share this article


      A new Sunlight survey of 1,000 U.S. peptide users finds that gray-market buyers visit the ER at 3x the rate of all peptide users. Three in four of these buyers have told their doctor about their peptide use, but the doctor never sees what was bought on social media.

      KIRKLAND, Wash., May 21, 2026 /PRNewswire/ -- Sunlight.com, a leading telehealth platform expanding access to personalized metabolic health and weight management care, released the findings of its Peptide Gray Market Report, revealing a fast-growing population of U.S. adults buying injectable peptides outside the regulated pharmacy system. While GLP-1 weight-loss drugs like Ozempic have dominated peptide coverage, the survey of 1,000 U.S. peptide users finds that the broader peptide market includes a substantial gray-market segment with sharply worse outcomes.

      The headline finding: 45% of peptide users who bought their peptides from Telegram, WhatsApp, or social media sellers have visited the emergency room or urgent care for a peptide reaction. The rate across all peptide users is 16%, making social-media buyers nearly 3x more likely to land in the ER.

      Key Findings

      • ER outcomes diverge by sourcing channel: Nearly half (45%) of peptide users who bought from Telegram, WhatsApp, or social media have visited the ER for a peptide reaction, compared to 1 in 6 (16%) across all peptide users.
      • Disclosure isn't oversight: 3 in 4 (76%) of social-media buyers have told their doctor about their peptide use, but the doctor never sees what was bought online.
      • The gray market is bigger than it looks: 1 in 7 (14.5%) of all peptide users have bought from Telegram, WhatsApp, or social media sellers.
      • AI is filling the dosing gap: 3 in 4 (75.5%) of peptide users have asked ChatGPT or another AI tool for peptide dosing or mixing instructions.
      • The knowledge gap: Peptide users without a doctor are 3x more likely not to know what they're injecting.

      The Gray Market Operates Alongside Clinical Care

      Most coverage of the peptide gray market has framed it as an underground population avoiding medicine. The survey data points the other direction. The peptide users most likely to land in the ER are not flying solo. They are people in active clinical care who layer non-prescription peptide purchases on top of their doctor's oversight.

      Among the social-media buyers in the survey, 3 in 4 (76%) had told their doctor about their peptide use. The clinical relationship was real. What was missing was visibility into what was being injected.

      Peptides bought through social-media channels bypass the doctor's prescription system. Many ship without the peptide name on the label, often under a "for research use only" framing the FDA has flagged as a legal loophole. The DEA has documented social media as a primary channel for unregulated drug sales, and NPR has recently reported on buyers in peptide enthusiast groups dealing directly with overseas factory representatives, paying by cryptocurrency and receiving shipments by mail.

      The pattern leaves clinical oversight doing half the work. The doctor sees the prescription. The doctor does not see what was bought outside the prescription system. That visibility gap is where the worst outcomes concentrate.

      Where Peptide Users Are Buying

      • A doctor or licensed healthcare provider: 62%
      • An online retailer or research chemical website: 30%
      • A U.S. compounding pharmacy: 30%
      • Telegram, WhatsApp, or a social media seller: 14.5%
      • An overseas supplier (China, South Korea, etc.): 10%
      • A friend or coworker: 6%

      The medical channels remain the largest single source. The gray-market segment is smaller in absolute share but accounts for a disproportionate share of adverse outcomes.

      AI Is Filling the Dosing Gap

      Most peptides bought outside the prescription system come without official dosing instructions, so users have turned to AI to figure out how much to take. AI use is not limited to people without a doctor. 78.8% of peptide users who told their doctor about their peptide use have also asked AI for dosing.

      "While the physician is supervising one layer of the patient's peptide use, the patient is self-managing other products through gray-market channels the physician has no visibility into. Disclosure does not equal oversight, and that creates a false sense of clinical coverage on both sides," said Dr. Angela Tran, board-certified physician in internal and obesity medicine and Chief Medical Advisor at Sunlight. "The gray-market products are not subject to a high tier of quality assurance, so the ER physician is often managing a contamination or sterility issue rather than a dosing error."

      For detailed insights on the Peptide Gray Market Report, access the full report at: https://www.sunlight.com/news/nearly-half-of-peptide-users-who-bought-on-social-media-ended-up-in-the-er/

      Methodology

      The findings presented are based on a survey conducted by Sunlight using Pollfish in May 2026. The survey collected responses from 1,000 U.S. adults who use, have purchased, or are considering injectable or oral peptides, and examined peptide sourcing channels, ER and urgent care visits, AI use for dosing, and knowledge of specific peptide products. Outcome questions referenced in this report were asked of the 518 respondents who reported having used or purchased peptides. All respondents passed a survey-wide attention check, and data collection adhered to Pollfish's quality control standards.

      About Sunlight

      Sunlight.com is a telehealth platform focused on expanding access to personalized metabolic health and weight management care. Sunlight connects users with licensed medical providers who, when clinically appropriate, may prescribe peptides, NAD+, and compounded GLP-1s like compounded semaglutide and compounded tirzepatide. The platform combines provider oversight, ongoing support, and convenient home delivery to simplify what has traditionally been a fragmented and inaccessible healthcare journey.

      As part of its commitment to transparency, Sunlight publishes original survey research and editorial reporting on weight loss, metabolic health, GLP-1 access, and emerging trends in clinical care. Sunlight's research has been cited by national health and consumer outlets. The company's mission is to help people build healthier, more sustainable lives by making metabolic and weight care more accessible and easier to navigate.

      Users can check eligibility through Sunlight's quiz or learn more about Sunlight's NAD+ program.

      For more, visit Sunlight.com

      Sources:

      • FDA on "research use only" framing for peptides: FDA Warning Letter to Summit Research Peptides (Dec 2024)
      • DEA on social media as a drug-sales channel: DEA Social Media Drug Trafficking Threat Overview (2022)
      • NPR on overseas peptide sourcing: "Chinese peptides" biohacking coverage (Jan 2026)

      SOURCE Sunlight

      Modal title

      Also from this source

      Sunlight.com Survey: 1 in 5 Hiring Managers Admit They're Less Likely To Hire Overweight Candidates

      Weight discrimination in the workplace is widespread, according to a new Sunlight.com survey of 1,000 U.S. hiring managers. The findings show weight...

      Sunlight.com Survey: GLP-1 Weight Loss Is Changing Dating and Relationships

      A new survey from Sunlight.com finds that significant weight loss from GLP-1 medications is reshaping romantic relationships, boosting confidence,...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Pharmaceuticals

      Pharmaceuticals

      Surveys, Polls and Research

      Surveys, Polls and Research

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.